Cargando…
Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
Rimegepant [Nurtec(®) ODT (USA); Vydura(®) (EU)] is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine with or without aura in adults, and for the preventive treatment of episodic migraine in adults. Rimegepant is available as an orally disinteg...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299922/ https://www.ncbi.nlm.nih.gov/pubmed/36739335 http://dx.doi.org/10.1007/s40263-023-00988-8 |